Soyoko Morimoto

1.1k total citations
37 papers, 388 citations indexed

About

Soyoko Morimoto is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Soyoko Morimoto has authored 37 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 24 papers in Immunology and 22 papers in Oncology. Recurrent topics in Soyoko Morimoto's work include Renal and related cancers (20 papers), Immunotherapy and Immune Responses (19 papers) and CAR-T cell therapy research (17 papers). Soyoko Morimoto is often cited by papers focused on Renal and related cancers (20 papers), Immunotherapy and Immune Responses (19 papers) and CAR-T cell therapy research (17 papers). Soyoko Morimoto collaborates with scholars based in Japan, Australia and United States. Soyoko Morimoto's co-authors include Haruo Sugiyama, Akihiro Tsuboi, Fumihiro Fujiki, Hiroko Nakajima, Yusuke Oji, Yoshitaka Oka, Naoki Hosen, Sumiyuki Nishida, Jun Nakata and Atsushi Kumanogoh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Soyoko Morimoto

35 papers receiving 384 citations

Peers

Soyoko Morimoto
Samuel John United States
Arafat Aljoufi United States
Guillermo O. Rangel Rivera United States
Alexandra Miggelbrink United States
Kirsten Nikolajsen Denmark
Ashley Pandolfi United States
Michiel F. van Oosterwijk Netherlands
Mirco Compagnone Italy
Sylvia Snauwaert Belgium
Eva Schlecker Germany
Samuel John United States
Soyoko Morimoto
Citations per year, relative to Soyoko Morimoto Soyoko Morimoto (= 1×) peers Samuel John

Countries citing papers authored by Soyoko Morimoto

Since Specialization
Citations

This map shows the geographic impact of Soyoko Morimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Soyoko Morimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Soyoko Morimoto more than expected).

Fields of papers citing papers by Soyoko Morimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Soyoko Morimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Soyoko Morimoto. The network helps show where Soyoko Morimoto may publish in the future.

Co-authorship network of co-authors of Soyoko Morimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Soyoko Morimoto. A scholar is included among the top collaborators of Soyoko Morimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Soyoko Morimoto. Soyoko Morimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hashii, Yoshiko, Hiroko Nakajima, Fumihiro Fujiki, et al.. (2023). Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. BMC Cancer. 23(1). 167–167. 5 indexed citations
2.
Fujiki, Fumihiro, Soyoko Morimoto, Kento Inoue, et al.. (2023). Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs. Cancer Immunology Immunotherapy. 72(7). 2347–2356. 1 indexed citations
3.
Nakagawa, Natsuki, Yoshiko Hashii, Hisako Kayama, et al.. (2022). An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia. Cancer Immunology Immunotherapy. 72(1). 39–53. 14 indexed citations
4.
Fujiki, Fumihiro, Soyoko Morimoto, Ayako Isotani, et al.. (2022). T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy. Frontiers in Immunology. 13. 935465–935465. 8 indexed citations
5.
Nakata, Jun, Kayako Isohashi, Yoshitaka Oka, et al.. (2021). Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics. 11(6). 1041–1041. 7 indexed citations
6.
Nakajima, Hiroko, Jun Nakata, Keiko Udaka, et al.. (2021). Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunology Immunotherapy. 70(11). 3323–3335. 6 indexed citations
7.
Fujiki, Fumihiro, Akihiro Tsuboi, Soyoko Morimoto, et al.. (2020). Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunology Immunotherapy. 70(1). 253–263. 7 indexed citations
8.
Tsuboi, Akihiro, Naoya Hashimoto, Fumihiro Fujiki, et al.. (2018). A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology Immunotherapy. 68(2). 331–340. 43 indexed citations
9.
Nakata, Jun, Hiroko Nakajima, Soyoko Morimoto, et al.. (2018). Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides. Oncotarget. 9(89). 36029–36038. 14 indexed citations
10.
Broos, Katrijn, Fumihiro Fujiki, Diana Campillo-Davó, et al.. (2018). A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget. 9(45). 27797–27808. 18 indexed citations
11.
Kondo, Kenta, Fumihiro Fujiki, Hiroko Nakajima, et al.. (2016). An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells. Journal of Immunotherapy. 39(3). 127–139. 2 indexed citations
12.
Hashimoto, Naoya, Akihiro Tsuboi, Naoki Kagawa, et al.. (2015). Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunology Immunotherapy. 64(6). 707–716. 34 indexed citations
13.
Hasegawa, Kana, Satomi Tanaka, Fumihiro Fujiki, et al.. (2015). An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. PLoS ONE. 10(12). e0144594–e0144594. 13 indexed citations
14.
Tatsumi, Naoya, Hiroyuki Sakamoto, Mari Fukuda, et al.. (2015). Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms. PLoS ONE. 10(6). e0130578–e0130578. 9 indexed citations
15.
Koido, Shigeo, Sumiyuki Nishida, Sadamu Homma, et al.. (2014). Abstract CT218: Wilms′ tumor gene 1 (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. Cancer Research. 74(19_Supplement). CT218–CT218. 2 indexed citations
16.
Nakata, Jun, Atsushi Okumura, Hidenori Kinoshita, et al.. (2013). In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity. Leukemia. 28(6). 1316–1325. 8 indexed citations
17.
Lin, Yu‐Hung, Fumihiro Fujiki, Yoshitaka Oka, et al.. (2013). HLA-DPB1*05. Journal of Immunotherapy. 36(3). 159–170. 16 indexed citations
18.
Tachino, Sho, Fumihiro Fujiki, Yoshitaka Oka, et al.. (2012). Functional human Th17 clones with WT1-specific helper activity. Cancer Immunology Immunotherapy. 62(4). 801–810. 1 indexed citations
19.
Nakajima, Hiroko, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2011). Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration. Vaccine. 30(4). 722–729. 16 indexed citations
20.
Nakamura, Miki, Soyoko Morimoto, Qifeng Yang, et al.. (2005). Osteoclast-like cells express receptor activity modifying protein 2: application of laser capture microdissection. Journal of Molecular Endocrinology. 34(1). 257–261. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel John Breakdown of academic impact, for papers by Arafat Aljoufi Breakdown of academic impact, for papers by Guillermo O. Rangel Rivera Breakdown of academic impact, for papers by Alexandra Miggelbrink Breakdown of academic impact, for papers by Kirsten Nikolajsen Breakdown of academic impact, for papers by Ashley Pandolfi Breakdown of academic impact, for papers by Michiel F. van Oosterwijk Breakdown of academic impact, for papers by Mirco Compagnone Breakdown of academic impact, for papers by Sylvia Snauwaert Breakdown of academic impact, for papers by Eva Schlecker
Rankless by CCL
2026